1. Medtech Insight
  2. >>Leadership

MTI Profile: US FDA's Second-In-Command Has Her Eye On A Tech-Forward Future

As principal deputy commissioner of the FDA, Amy Abernethy is focused on developing overarching policies that affect all its product centers. But perhaps what will stand as her legacy is her work to develop a data-centered strategy to improve how the agency reviews products and ensures their long-term safety and efficacy.

FDA Deputy Commissioner Amy Abernathy speaking at Reagan-Udall Foundation for FDA.(
As the second-in-command at the US FDA, Amy Abernethy is also tasked with developing the agency's technology needs • Source: Ferdous Al-Faruque

When Scott Gottlieb stepped down as commissioner for the US Food and Drug Administration earlier this summer, one name immediately rocketed to the top of the list as his potential replacement: Amy Abernethy, the agency's principal deputy commissioner.

As second-in-command at the agency, Abernethy is responsible for developing consistent policies across centers. She also serves as the FDA's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Viome’s CEO To Expand Into Clinical Diagnostics ‘For Which There Are No Solutions’ With AI, RNA Test

 
• By Marion Webb

Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.

Execs On The Move: October 27–31, 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

LinusBio Extends Hair-Based Diagnostic Beyond Autism, Expands Into Japan

 
• By Marion Webb

After rolling out its hair-based autism diagnostic across the US, LinusBio is expanding into Japan and testing its “molecular movie” technology for ALS and other neurological disorders, aiming to deliver the first objective biomarkers in pediatric and neuropsychiatric care.

Execs On The Move: October 20–24, 2025

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

More from Medtech Insight

Under Pressure: How To Safeguard The EU Responsible Person

 
• By Amanda Maxwell

The roles and responsibilities of EU medtech’s persons responsible for regulatory compliance vary widely in role and risk exposure. The recent TEAM-PRRC meeting highlighted how vulnerable they can be and the steps to protect themselves.

Viome’s CEO To Expand Into Clinical Diagnostics ‘For Which There Are No Solutions’ With AI, RNA Test

 
• By Marion Webb

Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.

Philips Ramps Up US Production, Seeks To Swiftly Move On From New FDA Warning Letter

 
• By Shubham Singh

Philips puts its latest “disappointing” warning letter into context, while announcing progress in regulatory performance, expanded US production and tariff resilience plans